Replies to post #357011 on Amarin Corp Plc (AMRN)

[Number sleven]

Invest, I think raf is correct. Based on an article posted earlier this week, CCSB won't be able to significantly increase API supply until 2023.
Sleven,

[gozips]

Pathetic that we hope the Chi-coms--the Chi-coms!!!--and socialized European medicine revive this company, which offers perhaps the best CVD drug per clinical trial outcomes data. Truly shows how pernicious the US patent/judicial/medical/insurance systems have become...ain't it great, Lovaza sales are increasing.

[rosemountbomber]

So what happens to a patient who has gotten the genV and goes in for a refill and there is none because of the limited supply? Do they get brand V and then balk because of the cost, or are they told "wait and we should have some generic V soon"?

I guess because this is the Amarin board that we don't have anyone posting who is using genV and come across that situation.